Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12613000885796
Ethics application status
Approved
Date submitted
5/08/2013
Date registered
8/08/2013
Date last updated
8/08/2013
Type of registration
Prospectively registered
Titles & IDs
Public title
Xuanju Compound Capsule VS Terazosin in treatment of chronic prostatitis: a Prospective Randomized Controlled Trial
Query!
Scientific title
Xuanju Compound Capsule compared with Terazosin in treatment of patients with chronic prostatitis: evaluation of symptom and NIH-CPSI
Query!
Secondary ID [1]
282965
0
Nil
Query!
Universal Trial Number (UTN)
U1111-1146-3373
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
chronic prostatitis
289788
0
Query!
Condition category
Condition code
Renal and Urogenital
290140
290140
0
0
Query!
Other renal and urogenital disorders
Query!
Alternative and Complementary Medicine
290169
290169
0
0
Query!
Other alternative and complementary medicine
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
xuanju compound capsule in treatment of chronic prostatitis; 1.26mg oral administrated 3 times daily for 12 weeks; keeping diary for taking medicine
Query!
Intervention code [1]
287672
0
Treatment: Other
Query!
Comparator / control treatment
Terazosin in treatment of chronic prostatitis; 2mg oral tablet once daily for 12 weeks; keeping diary for taking medicine
Query!
Control group
Active
Query!
Outcomes
Primary outcome [1]
290169
0
chronic prostatis symptoms assessed by NIH-CPSI score
Query!
Assessment method [1]
290169
0
Query!
Timepoint [1]
290169
0
3 months later after treatment
Query!
Secondary outcome [1]
304042
0
immune function asseessed by serum CD4,CD8,IgA, IgM, IgG, IL-2,IL-8, TNF-a
Query!
Assessment method [1]
304042
0
Query!
Timepoint [1]
304042
0
3 months later after teatment
Query!
Secondary outcome [2]
304082
0
VAS assessed by pain tools
Query!
Assessment method [2]
304082
0
Query!
Timepoint [2]
304082
0
3 months later after teatment
Query!
Eligibility
Key inclusion criteria
1.consistent with chronic non-bacterial prostatitis diagnosis, duration >3 months;
2.aged 18 to 50 years old;
3.Chronic Prostatitis Symptom Index (NIH-CPSI) >11 points;
4.immune dysfunction; (recommended results based on pre-select several sensitive indicators);
5.voluntarily signed informed consent.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
50
Years
Query!
Query!
Sex
Males
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
1.except for I,II, IV type of prostatitis patients;
2.pelvic area pain, voiding dysfunction patients, benign prostatic hyperplasia, prostate cancer, testicular epididymis and spermatic cord disease, overactive bladder, neurogenic bladder, interstitial cystitis, bladder gland , sexually transmitted diseases, bladder cancer, anorectal disease, lumbar disease, central and peripheral neuropathy;
3.local pain as the main manifestation of the patients, specifically by the ureteral stones, bladder stones, inguinal hernia, pubic inflammation, varicocele, epididymitis, colorectal disease, caused by low back myofascial go far;
4.severe neurosis, mental illness;
5.past month have used drugs for treating chronic prostatitis or other relevant treatment;
6.associated with cardiovascular, cerebrovascular, liver and kidney and hematopoietic system in patients with severe primary disease, liver function ALT and / or AST> 1.5 times the upper limit of normal persons;
7.allergies, or known of the test drug ingredients or terazosin drugs have allergies;;
8.participating in the other clinical trials in a past month;
9.researchers consider it inappropriate to participate in clinical trials.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Safety/efficacy
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Not yet recruiting
Query!
Date of first participant enrolment
Anticipated
1/02/2014
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
1000
Query!
Accrual to date
Query!
Final
Query!
Recruitment outside Australia
Country [1]
5265
0
China
Query!
State/province [1]
5265
0
Query!
Country [2]
5285
0
Korea, Democratic People's Republic Of
Query!
State/province [2]
5285
0
Query!
Funding & Sponsors
Funding source category [1]
287739
0
Hospital
Query!
Name [1]
287739
0
shanghai changhai hospital
Query!
Address [1]
287739
0
changhai road 168#, shanghai , China;200433
Query!
Country [1]
287739
0
China
Query!
Primary sponsor type
Individual
Query!
Name
zhou tie
Query!
Address
shanghai changhai hospital;changhai road 168#, shanghai , China;200433
Query!
Country
China
Query!
Secondary sponsor category [1]
286465
0
Individual
Query!
Name [1]
286465
0
sun yinghao
Query!
Address [1]
286465
0
shanghai changhai hospital;changhai road 168#, shanghai , China;200433
Query!
Country [1]
286465
0
China
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
289691
0
changhai hospital ethic committee
Query!
Ethics committee address [1]
289691
0
changhai road 168#, shanghai , China;200433
Query!
Ethics committee country [1]
289691
0
China
Query!
Date submitted for ethics approval [1]
289691
0
Query!
Approval date [1]
289691
0
29/07/2013
Query!
Ethics approval number [1]
289691
0
Query!
Summary
Brief summary
Immune dysfunction has been thought of to be involved in patients with chronic prostatitis. Thus we use xuanju compound capsule, a traditional chinese drug, to treat chronic prostatitis and terazosin used in control group. XUANJU capsule is a kind of chinese traditional drug and has the role in immunoregulation. If xuanju capsule indeed improve the symptom of patients with chronic prostatitis, will give strong evidence to demonstrate the important role of immune regulation in treatment of chronic prostatitis.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
41990
0
Prof zhou tie
Query!
Address
41990
0
shanghai changhai hospital;changhai road 168#, shanghai , China;200433
Query!
Country
41990
0
China
Query!
Phone
41990
0
+86 2113918360523
Query!
Fax
41990
0
Query!
Email
41990
0
[email protected]
Query!
Contact person for public queries
Name
41991
0
Prof zhou tie
Query!
Address
41991
0
shanghai changhai hospital;changhai road 168#, shanghai , China;200433
Query!
Country
41991
0
China
Query!
Phone
41991
0
+86 2113918360523
Query!
Fax
41991
0
Query!
Email
41991
0
[email protected]
Query!
Contact person for scientific queries
Name
41992
0
Prof zhou tie
Query!
Address
41992
0
shanghai changhai hospital;changhai road 168#, shanghai , China;200433
Query!
Country
41992
0
China
Query!
Phone
41992
0
+86 2113918360523
Query!
Fax
41992
0
Query!
Email
41992
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF